Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation
Résumé
Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intrapatient variability (tacrolimus IPV) is an emerging risk factor associated with poor graft outcomes after solid organ transplantations. Here, we examined the modifications of tacrolimus IPV after switching to a different formulation of tacrolimus. Experimental Approach: We identified 353 solid organ transplant recipients that were switched in our center from immediate-release (IR-tacrolimus) or prolonged-release tacrolimus (PR-tacrolimus) to extended-release, LCP-tacrolimus (LCP-tacrolimus). Among them, 54 patients underwent at least 3 available tacrolimus blood concentrations before and after the switch, allowing us to investigate tacrolimus IPV.
Mots clés
tacrolimus variability
solid organ transplantation
tacrolimus formulation
extended-release tacrolimus
outcomes
rejection Intrapatient variability
IPV
DSA
donor-specific antibodies
IR-tac
immediate-release tacrolimus
PR-tac
prolonged-release tacrolimus
LCP-tac
once-daily extended-release tacrolimus
MPA
mycophenolic Acid
Fichier principal
2021_Del Bello_Frontiers pharmacology- Tacrolimus intrapatient.pdf (1.16 Mo)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité
Licence : CC BY - Paternité
